Sanofi plans to buy back $152M in Genzyme CVRs

Sanofi ($SNY) plans to buy back up to $152 million in contingent value rights linked to last year's buyout of Genzyme. The French drugmaker says it would purchase about 30% of the CVRs, which pay off if certain Genzyme sales targets are met. The move is seen as a sign that Sanofi is confident that the multiple sclerosis drug Lemtrada will be as lucrative as hoped. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.